Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/7194
Title: | Simvastatin may improve myocardial perfusion abnormality in slow coronary flow | Authors: | Cakmak, M. Tanriverdi, H. Cakmak, N. Evrengul, H. Cetemen, S. Kuru, O. |
Keywords: | Atherosclerosis Endothelial function Myocardial ischemia Slow coronary flow Statin TIMI frame count methoxy isobutyl isonitrile technetium tc 99m nitrate simvastatin adult angina pectoris article blood clot lysis controlled study coronary artery blood flow correlation analysis female follow up heart infarction heart muscle perfusion human major clinical study male myocardial disease priority journal single drug dose single photon emission computer tomography Adult Angina Pectoris Blood Chemical Analysis Blood Flow Velocity Chest Pain Cholesterol, HDL Cholesterol, LDL Coronary Angiography Coronary Circulation Dose-Response Relationship, Drug Drug Administration Schedule Female Follow-Up Studies Humans Middle Aged Probability Prospective Studies Risk Assessment Simvastatin Statistics, Nonparametric Tomography, Emission-Computed, Single-Photon Treatment Outcome |
Abstract: | Background: The slow coronary flow (SCF) phenomenon is a coronary microvascular disorder characterized by the delayed passage of contrast in the absence of obstructive epicardial coronary disease. Recent studies showed the possible role of endothelial dysfunction, diffuse atherosclerosis and inflammation in the pathogenesis of this phenomenon. We aimed to investigate the effect of statin on myocardial perfusion in patients with SCF. Methods and Results: The study population consisted of 97 patients with SCF. Coronary flow patterns of the cases are determined by thrombolysis in myocardial infarction (TIMI) frame count method. Single-photon emission computed tomographic myocardial perfusion imaging studies and lipid parameters of the patients were obtained before and after 6 months of simvastatin treatment period. During the study, daily single dose of 40 mg simvastatin has been given to each subject. We found a significant positive correlation between mean TIMI frame count and basal reversibility score (r = 0.84, p = 0.0001). In addition, analysis of the reversibility scores demonstrates that simvastatin treatment has significantly improved the myocardial perfusion abnormality at the end of the follow-up period. Conclusion: Present findings allow us to conclude that simvastatin improved myocardial perfusion in patients with SCF. Copyright © 2007 S. Karger AG. | URI: | https://hdl.handle.net/11499/7194 https://doi.org/10.1159/000109405 |
ISSN: | 0008-6312 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
SCOPUSTM
Citations
44
checked on Sep 30, 2024
WEB OF SCIENCETM
Citations
40
checked on Sep 30, 2024
Page view(s)
40
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.